Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Ginkgo Bioworks Q3 2025 Earnings Call - AI-Driven Autonomous Labs Set to Transform Biotechnology
Ginkgo Bioworks reported a mixed Q3 2025 with cell engineering revenues down 61% year-over-year, primarily due to non-recurring revenue items and ongoing program rationalizations. The company highligh...
- Ginkgo's Q3 2025 cell engineering revenue fell 61% year-over-year, impacted by a $45 million non-cash revenue credit in 2024 and program rationalizations.
- Biosecurity segment generated $9 million revenue with a 19% gross margin, improving operating loss by 21% year-over-year.
- Adjusted EBITDA declined to negative $56 million due to Google Cloud shortfall expenses and absence of Motif Foodworks revenue credits.
- +9 more takeaways
BuzzFeed Q3 2025 Earnings Call - Navigating Revenue Headwinds with Lean Operations and Audience Strength
BuzzFeed’s Q3 2025 results underscore a tough advertising and commerce landscape, with total revenues dipping 17% year-over-year to $46.3 million, reflecting softer direct-sold advertising, reduced af...
- Q3 2025 total revenue declined 17% year-over-year to $46.3 million due to weaker advertising demand, affiliate bonuses, and tough presidential cycle comps.
- Adjusted EBITDA remained positive at $753,000, down significantly from $8.1 million in Q3 2024 but reflecting operational discipline.
- Advertising revenue fell 11% to $22.2 million, with direct-sold advertising particularly soft at $5.1 million.
- +9 more takeaways
Pacira BioSciences Q3 2025 Earnings Call - Exparel Volume Growth Accelerates Driving Raised Full-Year Guidance
Pacira BioSciences reported a strong third quarter with a 6% year-over-year revenue increase propelled by a 9% surge in Exparel volumes, the highest growth seen in three years. The company raised full...
- Pacira posted 6% revenue growth year-over-year in Q3 2025, driven principally by Exparel and iovera.
- Exparel volume grew approximately 9%, the fastest quarterly growth in over three years, underscoring success of recent commercial investments.
- Company raised full-year non-GAAP gross margin guidance to 80%-82%, citing manufacturing efficiencies and elimination of Exparel royalties.
- +9 more takeaways
Beauty Health Company 2025 Third Quarter Earnings Call - Stabilizing Device Sales Amid Macro Pressures with Focus on Consumables
Beauty Health Company reported Q3 2025 revenues of $70.7 million, down 10.3% year-over-year, with device sales dropping 24.6% largely due to global equipment softness and a transitional distributor mo...
- Q3 2025 net sales declined 10.3% year-over-year to $70.7 million, with device sales down 24.6% reflecting global softness and China distributor transition.
- Consumables sales fell 2.6%, but would have increased modestly excluding China’s model change, now comprising 71% of total revenue, up from 65% last year.
- HydroFacial installed base grew to 35,409 active units, adding 875 devices in the quarter, showing footprint expansion despite device sale pressures.
- +7 more takeaways
Take-Two Interactive Q2 FY2026 Earnings Call - Record-Breaking Net Bookings and Raised Fiscal Outlook Despite GTA VI Delay
Take-Two Interactive reported an outstanding second quarter for fiscal 2026, smashing expectations with net bookings of $1.96 billion, their best Q2 ever. The stellar performance was driven by franchi...
- Take-Two delivered record second quarter net bookings of $1.96 billion, surpassing guidance and marking the highest Q2 in company history.
- NBA 2K26 launched with strong sales (5 million+ units) and significant recurrent consumer spending growth of 45%, driven by premium SKUs and enhanced game features.
- Mobile business outperformed substantially, with hits like Toon Blast (+26% YoY), Match Factory (+20% YoY), and Color Block Jam achieving record net bookings.
- +10 more takeaways
Unusual Machines 3Q 2025 Earnings Call - First Profitable Quarter Marks Start of Rapid Growth and Onshoring Success
Unusual Machines reported its first ever profitable quarter in Q3 2025, a milestone achieved amid sustained revenue growth and expanding enterprise sales. The company’s strategic pivot from retail to ...
- Q3 marked Unusual Machines’ first profitable quarter with $2.1 million in revenue, a 39% year-over-year increase.
- The shift to enterprise sales is clear: over 50% of Q3 revenue came from enterprise customers, with $16 million in purchase orders on hand.
- Gross margins improved significantly from 28% to 34% year-to-date, indicating better product mix and operational efficiency.
- +11 more takeaways
Nephros Q3 2025 Earnings Call - Strong Revenue Growth Fueled by Programmatic Sales and New PFAS Solution
Nephros delivered $4.8 million in Q3 2025 revenue, marking their second-highest quarter ever and a 35% year-over-year increase. This quarter also represented their fifth consecutive quarter of profita...
- Nephros achieved $4.8 million revenue in Q3 2025, up 35% YoY, driven by programmatic business and installation services.
- The Filtration Installation Program is a major growth lever, increasing reorder rates and deepening customer engagement.
- Q3 marks the fifth consecutive quarter of profitability with net income of $337,000 and positive adjusted EBITDA of $418,000.
- +13 more takeaways
HCI Group 3Q 2025 Earnings Call - Exio IPO Unlocks Intrinsic Value and Bolsters Book Value
HCI Group reported another strong quarter in 3Q 2025, posting $4.90 earnings per share on a pre-tax income of over $90 million, with a notably low combined ratio of 64% and a loss ratio improvement to...
- HCI posted $4.90 diluted earnings per share for 3Q 2025 with pre-tax income over $90 million, marking a solid quarter.
- The net combined ratio dropped to 64%, aided by a 22% loss ratio, one of the lowest recent levels, helped by favorable Florida weather.
- Year-to-date book value per share increased over 50% to $63, with shareholder equity exceeding $820 million.
- +12 more takeaways
Sensus Healthcare Q3 2025 Earnings Call - CMS Grants SRT Its Own CPT Codes with 300%+ Reimbursement Boost
In Q3 2025, Sensus Healthcare recorded revenues of $6.9 million, down from $8.8 million a year ago, due mainly to fewer unit sales to a large customer. Despite this, the company is buoyed by a landmar...
- CMS issued first dedicated CPT codes for superficial radiotherapy (SRT) treating non-melanoma skin cancer and keloids, increasing reimbursement per fraction by over 300%.
- This new coding significantly narrows reimbursement disparities between office-based treatments and hospital outpatient rates, enhancing ROI for SRT devices.
- Sensus shipped 16 SRT systems in Q3 2025, including three to China, bringing global system sales past 900 units with a 2026 target of 1,000 units.
- +12 more takeaways
AVITA Medical Q3 2025 Earnings Call - Reimbursement Clarity Sets Stage for Revenue Recovery
AVITA Medical reported a challenging Q3 2025 with $17 million in revenue, falling short of expectations due primarily to reimbursement disruption caused by new CMS CPT codes and delays in Regional Med...
- Q3 2025 revenue totaled $17.1 million, a 13% decline year-over-year, impacted by reimbursement delays and hospital VAC review pacing.
- Full-year 2025 revenue guidance was lowered from $76M-$81M to $70M-$74M due to slower than expected reimbursement normalization.
- New Category 1 CPT codes for ReCell took effect in January 2025 without national payment rates from CMS, leaving rate setting to regional MACs.
- +13 more takeaways